Insurers balk at paying for Biogen's $56,000-a-year Alzheimer's treatment
by John Tozzi, Angelica Lavito and Anushree DaveCredit: CC0 Public DomainU.S. health insurers say they want more proof before paying for Biogen Inc.'s Aduhelm, stalling sales of the costly new Alz
Updated on: April 29,2024
17

Insurers balk at paying for Biogen's $56,000-a-year Alzheimer's treatment
by John Tozzi, Angelica Lavito and Anushree DaveCredit: CC0 Public DomainU.S. health insurers say they want more proof before paying for Biogen Inc.'s Aduhelm, stalling sales of the costly new Alz
Updated on:April 29,2024
17
